Display options
Cite
Hagag AA, El-Lateef AE. Prognostic value of brain and acute leukemia cytoplasmic gene expression in egyptian children with acute myeloid leukemia. Mediterr J Hematol Infect Dis. 2015;7(1):e2015033doi: 10.4084/MJHID.2015.033.
Hagag, A. A., & El-Lateef, A. E. (2015). Prognostic value of brain and acute leukemia cytoplasmic gene expression in egyptian children with acute myeloid leukemia. Mediterranean journal of hematology and infectious diseases, 7(1), e2015033. https://doi.org/10.4084/MJHID.2015.033
Hagag, Adel A, and El-Lateef, Amal Ezzat Abd. "Prognostic value of brain and acute leukemia cytoplasmic gene expression in egyptian children with acute myeloid leukemia." Mediterranean journal of hematology and infectious diseases vol. 7,1 (2015): e2015033. doi: https://doi.org/10.4084/MJHID.2015.033
Hagag AA, El-Lateef AE. Prognostic value of brain and acute leukemia cytoplasmic gene expression in egyptian children with acute myeloid leukemia. Mediterr J Hematol Infect Dis. 2015 Apr 20;7(1):e2015033. doi: 10.4084/MJHID.2015.033. eCollection 2015. PMID: 25960861; PMCID: PMC4418372.
Copy Download .nbib Format: NLM
Share it on

Mediterr J Hematol Infect Dis. 2015 Apr 20;7(1):e2015033. doi: 10.4084/MJHID.2015.033. eCollection 2015.

Prognostic value of brain and acute leukemia cytoplasmic gene expression in egyptian children with acute myeloid leukemia.

Mediterranean journal of hematology and infectious diseases

Adel A Hagag, Amal Ezzat Abd El-Lateef

Affiliations

  1. Department of Pediatrics, Faculty of Medicine, Tanta University, Egypt.
  2. Department of Clinical Pathology, Faculty of Medicine, Tanta University, Egypt.

PMID: 25960861 PMCID: PMC4418372 DOI: 10.4084/MJHID.2015.033

Abstract

BACKGROUND: Acute myeloid leukemia (AML) accounts for 25%-35% of acute leukemia in children. BAALC gene (Brain and Acute Leukemia Cytoplasmic gene) is a recently identified gene on chromosome 8q22.3 that has prognostic significance in AML. The aim of this work was to study the impact of BAALC gene expression on prognosis of AML in Egyptian children.

PATIENTS AND METHODS: This study was conducted on 40 Egyptian children with newly diagnosed AML who were subjected to full history taking, clinical examination and laboratory investigations including: complete blood count, LDH, bone marrow aspiration, cytochemistry, immunophenotyping and assessment of BAALC Gene by real time PCR in bone marrow aspirate mononuclear cells before the start of chemotherapy.

RESULTS: Positive BAALC gene expression was found in 24 cases (60%) and negative expression in 16 cases (40%). Positive BAALC gene expression group includes 14 males and 10 females with mean age at presentation of 8.35±2.63 while negative BAALC gene expression includes 10 males and 6 females with mean age at presentation of 7.74±3.23 with no statistically significant differences between patients with positive and negative BAALC gene expression regarding age, sex and clinical presentations at time of diagnosis including pallor, purpura, splenomegaly, hepatomegaly and lymphadenopathy and laboratory investigations including WBCs and platelets counts, hemoglobin and LDH levels, and peripheral blood and bone marrow blast cell counts. There was significant association between positive BAALC gene expression and M1 and M2 compared with negative BAALC gene expression which is significantly associated with M4. There were statistically significant differences in disease outcome between positive and negative BAALC gene expression groups with higher rate of relapse and death and lower rate of complete remission and disease free survival in positive BAALC gene expression group compared with negative BAALC gene expression group. (p = 0.017).

CONCLUSION AND RECOMMENDATION: BAALC expression is an important bad prognostic factor in AML patients with normal karyotype and therefore we recommend its incorporation into novel risk-adapted therapeutic strategies to improve the currently disappointing cure rate of patients with AML.

References

  1. Cancer Cell. 2006 Mar;9(3):189-98 - PubMed
  2. Ann Hematol. 2004;83 Suppl 1:S108-12 - PubMed
  3. Klin Onkol. 2012;25(1):26-35 - PubMed
  4. Blood. 2007 Jan 15;109(2):431-48 - PubMed
  5. Blood. 2003 Sep 1;102(5):1613-8 - PubMed
  6. Clin Lab. 2013;59(5-6):621-8 - PubMed
  7. Clin Cancer Res. 2005 Feb 15;11(4):1416-24 - PubMed
  8. J Clin Oncol. 2007 Aug 20;25(24):3739-45 - PubMed
  9. Scand J Clin Lab Invest Suppl. 1968;97:77-89 - PubMed
  10. Am J Hematol. 2013 Oct;88(10):848-52 - PubMed
  11. Cancer. 2006 Feb 15;106(4):950-6 - PubMed
  12. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13901-6 - PubMed
  13. Ann Hematol. 2010 May;89(5):453-8 - PubMed
  14. Blood. 2010 Jan 21;115(3):453-74 - PubMed
  15. Leuk Lymphoma. 2014 Mar;55(3):662-7 - PubMed
  16. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6668-73 - PubMed
  17. Br J Haematol. 2011 Nov;155(3):366-76 - PubMed
  18. Blood. 2010 Aug 19;116(7):1132-5 - PubMed
  19. Best Pract Res Clin Haematol. 2001 Mar;14(1):19-47 - PubMed
  20. Blood Cancer J. 2014 Jan 10;4:e173 - PubMed
  21. Blood Cells Mol Dis. 2014 Sep;53(3):144-8 - PubMed
  22. Leuk Res. 2011 May;35(5):685-8 - PubMed
  23. Blood. 2012 Apr 26;119(17):3890-9 - PubMed
  24. Blood. 2002 Dec 15;100(13):4325-36 - PubMed
  25. Mediterr J Hematol Infect Dis. 2011;3(1):e2011055 - PubMed
  26. J Clin Oncol. 2006 Feb 10;24(5):790-7 - PubMed

Publication Types